Adaptive Biotechnologies COO Sells Shares Following Option Exercise
Adaptive Biotechnologies' COO, Julie Rubinstein, sold 57,180 shares of the company's stock, valued at approximately $758,000, following the exercise of options between April 9 and April 13, 2026. The sale represents 11.95% of her direct shareholding, though she still holds a significant equity position through remaining stock options. The transaction has raised questions about the implications for the company's stock and Rubinstein's ongoing ownership.
Tickers: $ADPT
Topics: corporate governance executive stock sales SEC filings stock market activity